Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
Zevra Therapeutics revealed that the US Food and Drug Administration (FDA) has indicated it will convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee (GeMDAC) on August 2, 2024, to review the New Drug Application (NDA) for arimoclomol. 15 July 2024
Dermatology specialist Journey Medical has announced positive top-line results from two Phase III trials of its rosacea candidate, DFD-29, a formulation of minocycline hydrochloride. 11 July 2023
China-based Brii Biosciences says that it has entered into license agreements with US firm VBI Vaccines, expanding the companies’ collaboration in the hepatitis B virus (HBV) field. 11 July 2023
The safety monitoring committee of the European Medicines Agency is to investigate a potential connection between the use of certain Novo Nordisk products and suicidal thoughts. 11 July 2023
A report commissioned by Pharmaceutical Research and Manufacturers of America (PhRMA), the trade group representing big pharma in the USA, has highlighted the role of post-approval research and development (R&D) in advancing cancer treatment options. 10 July 2023
The New Drug Application (NDA) submission for lurbinectedin has been accepted by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after receiving platinum-based chemotherapy. 10 July 2023
There was plenty of hype and hope attached to the arrival of Spravato (esketamine nasal spray) as a treatment for depression when it first started to be launched in major markets more than four years ago. 10 July 2023
UK-based drugmaker GSK has secured approval in its home country for the breakthrough respiratory syncytial virus (RSV) vaccine, Arexvy (respiratory syncytial virus vaccine). 10 July 2023
Regarding the Greek National Organization for Medicines (EOF) announcement on the issue of shortages, the trade group Hellenic Association of Pharmaceutical Companies (SFEE) has issued its views. 10 July 2023
Brazil’s Oswaldo Cruz Institute (IOC/Fiocruz) and the Agostinho Neto University (UAN), in Luanda, Angola), have signed a memorandum of understanding for future partnerships in teaching and research between the institutions 10 July 2023
Swiss pharma giant Novartis yesterday announced that the US District Court for the District of Delaware issued a negative decision regarding the validity of a patent covering its heart failure treatment Entresto and combinations of sacubitril and valsartan, which expires in 2025 with its pediatric exclusivity. 8 July 2023
The US Department of Health and Human Services (HHS) today announced actions to protect consumers from junk health plans, surprise medical bills, and excess costs that lead to medical debt. 7 July 2023
The US Food and Drug Administration (FDA) has removed the partial clinical hold on the TakeAim Leukemia Phase I/II study of emavusertib for the treatment of hematologic malignancies, conducted by US biotech Curis. 7 July 2023
Privately-held Italian drugmaker Chiesi Farmaceutici has appointed Alessandro Chiesi as chairman of the Chiesi Group. Additionally, it said that Maria Paola Chiesi becomes vice chair. 7 July 2023
Shares of US clinical-stage drug developer Histogen rocketed 33% to $$0.97 in after-hours trading yesterday, after it indicated that the company could be up for sale. 7 July 2023
The European Medicines Agency (EMA), the European Commission (EC) and the Heads of Medicines Agencies (HMA) are phasing out the extraordinary regulatory flexibilities for medicines put in place during the COVID-19 pandemic to help address regulatory and supply challenges arising from the pandemic. 7 July 2023
Wuppertal, Germany-based infectious disease drug developer AiCuris Anti-infective Cures today announced that it has sharpened its strategic focus on the development of novel, therapeutic candidates for the prevention and treatment of moderate to severe and 6 July 2023
The UK-based non-profit medical research organization and charity LifeArc has announced a program to invest more than £100 million ($127 million) by 2030 to deliver new breakthroughs in rare diseases. 6 July 2023
Shorla Oncology, a privately-held, female founded US-Ireland pharmaceutical company, today announced it has entered into a licensing agreement and strategic partnership with a UK-based innovative drug development and manufacturing company. 6 July 2023
The Foreign Direct Investment (FDI) equity inflow into the pharmaceutical industry in India has jumped by 45.4% in the fiscal year ended March 2023, compared to inflow in the previous fiscal year. 6 July 2023